Introduction: Little is known about the heterogeneous treatment effects of metformin on dementia risk in people with type 2 diabetes (T2D).
Methods: Participants (≥ 50 years) with T2D and normal cognition at baseline were identified from the National Alzheimer's Coordinating Center database (2005-2021). We applied a doubly robust learning approach to estimate risk differences (RD) with a 95% confidence interval (CI) for dementia risk between metformin use and no use in the overall population and subgroups identified through a decision tree model.
Results: Among 1393 participants, 104 developed dementia over a 4-year median follow-up. Metformin was significantly associated with a lower risk of dementia in the overall population (RD, -3.2%; 95% CI, -6.2% to -0.2%). We identified four subgroups with varied risks for dementia, defined by neuropsychiatric disorders, non-steroidal anti-inflammatory drugs, and antidepressant use.
Discussion: Metformin use was significantly associated with a lower risk of dementia in individuals with T2D, with significant variability among subgroups.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10917005 | PMC |
| http://dx.doi.org/10.1002/alz.13480 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Resistance training protects the hippocampus and precuneus against atrophy and benefits white matter integrity in older adults with mild cognitive impairment.
Geroscience
January 2025
Laboratory of Imaging and Biomarkers in Cognitive Disorders, School of Medical Sciences, Universidade Estadual de Campinas, Campinas, Brazil.
Mild cognitive impairment (MCI) refers to cognitive alterations with preservation of functionality. Individuals with this diagnosis have a higher risk of developing dementia. Non-pharmacological interventions, such as physical exercise, are beneficial for the cognition of this population.
View Article and Find Full Text PDFPsoriasis and dementia: A population-based matched cohort study of adults in England.
Ann Clin Transl Neurol
January 2025
Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
Objective: Evidence for an association between psoriasis and dementia is limited and conflicting. We aimed to investigate the association using large and representative population-based data and describe risk by dementia subtype and over time.
Methods: We compared dementia risk between people with and without psoriasis using an age-, sex- and primary care practice-matched cohort of adults aged ≥40 years from the Clinical Practice Research Datalink Aurum in England (1997-2021) linked to hospital admissions data, analysed with stratified Cox regression.
Endothelial cells as key players in cerebral small vessel disease.
Nat Rev Neurosci
January 2025
UK Dementia Research Institute, The University of Edinburgh, Edinburgh, UK.
Cerebral small vessel disease (SVD) is a vascular disorder that increases the risk of stroke and dementia and is diagnosed through brain MRI. Current primary prevention and secondary treatment of SVD are focused on lifestyle interventions and vascular risk factor control, including blood pressure reduction. However, these interventions have limited effects, a proportion of individuals with sporadic SVD do not have hypertension, and SVD shows strong familial and genetic underpinnings.
View Article and Find Full Text PDFRisks of Dementia Associated With Anticholinergic Medication Compared to Beta-3 Agonist Among Older Patients With Overactive Bladder in Japan: The LIFE Study.
Int J Geriatr Psychiatry
January 2025
Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Article Synopsis
- Anticholinergic drugs may lead to cognitive impairment, and this study specifically examined their risk of causing dementia in older adults in Japan compared to beta-3 agonists.
- The study involved over 1.4 million participants, with nearly 13,500 taking anticholinergics and around 24,700 using beta-3 agonists, all aged 65 and older with overactive bladder.
- Results indicated that users of anticholinergic drugs had a 22% higher risk of developing dementia compared to those using beta-3 agonists, suggesting a significant association between anticholinergic use and increased dementia risk.
The effect of Amyloid and Tau Co-pathology on disease progression in Lewy body dementia: A systematic review.
Parkinsonism Relat Disord
December 2024
Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Co-morbid Alzheimer's disease (AD) pathology (amyloid-beta and tau) is commonly observed in Lewy body dementia (LBD), and this may affect clinical outcomes. A systematic review of the effect of AD co-pathology on longitudinal clinical outcomes in LBD was conducted. A search of MEDLINE and EMBASE (October 2024) yielded n = 3558 records that were screened by two independent reviewers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!